Patent application number | Description | Published |
20090070236 | Diamond and Precious Stone Trading Platform with Funding and Delivery Transparency - The transparent diamond and precious stone trading platform and method has funding and delivery transparency during the buy-order, funding, and tracking pickup, independent comparative inspection, and final delivery of each stone. The database of stones includes, for each stone, stone-weight, stone characteristics, price, and a grading lab certificate. The certificate uniquely identifies each stone and is electronically accessible by sellers, buyers, couriers, and authentication services. A buy command is communicated to seller and buyer. The transfer funds is electronically noted and communicated. The pickup by courier, interim delivery, inspection comparing the stone to the certificate, and subsequent delivery to buyer and release of funds is communicated to traders by emails, text messages, automated voice messages or IVR. Buyer and seller profiles establish communications channels and organizational managers are also permitted access and given communications. If time or place parameters are exceeded, increasing levels of alarm electronic communications are implemented. | 03-12-2009 |
20090125435 | Trading Plaftorm System and Method for Diamond and Precious Stone Transactions - The transaction method and system facilitates sales of diamonds or stones. A searchable database of stones includes, for each stone, an offer to sell, a weight-carat, other stone characteristics and an electronic copy of a grading lab certificate which uniquely identifies each stone from all other stones in the database. A search displays, for each stone, the offer and stone weight, stone characteristics and electronic access to the stone's certificate. The system permits a prospective buyer to “buy now,” which closes the transaction at the posted offer, or “bid now” wherein the system logs a bid value and an expiry time. Other bids are posted and displayed, in a primacy order until (a) the seller “buy now at the bid” or (b) withdraws the offer or (c) replaces the offer with a subsequent offer. Preferably, offers: displayed in time sequence and bids: displayed by primacy of price and expiry. | 05-14-2009 |
Patent application number | Description | Published |
20100292134 | Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury - This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels. The invention also provides a method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to prevent exaggerated restenosis in the subject. | 11-18-2010 |
20110126298 | Transgenic Mice Over-Expressing Receptor For Advanced Glycation Endproduct (RAGE) In Brain And Uses Thereof - The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence. | 05-26-2011 |
20120291145 | TRANSGENIC MICE OVER-EXPRESSING RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCT (RAGE) IN BRAIN AND USES THEREOF - The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence. | 11-15-2012 |
Patent application number | Description | Published |
20090274667 | RETINAL PIGMENT EPITHELIAL STEM CELLS - The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment. | 11-05-2009 |
20100021422 | METHODS AND COMPOSITIONS FOR DELIVERY OF EXOGENOUS FACTORS TO NERVOUS SYSTEM SITES - The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems. | 01-28-2010 |
20110217264 | METHODS AND COMPOSITIONS FOR DELIVERY OF EXOGENOUS FACTORS TO NERVIOUS SYSTEM SITES - The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems. | 09-08-2011 |
20120003736 | METHODS FOR CULTURING UNDIFFERENTIATED CELLS USING SUSTAINED RELEASE COMPOSITIONS - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state. | 01-05-2012 |
20130330302 | RETINAL PIGMENT EPITHELIAL STEM CELLS - The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment. | 12-12-2013 |
20130337562 | METHODS FOR CULTURING UNDIFFERENTIATED CELLS USING SUSTAINED RELEASE COMPOSITIONS - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state. | 12-19-2013 |
20150051212 | Compositions And Methods For Inhibiting Drusen - Described herein are methods for inhibiting drusen. | 02-19-2015 |
20150064784 | Methods For Culturing Undifferentiated Cells Using Sustained Release Compositions - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state. | 03-05-2015 |
20150148383 | Methods for Inhibiting or Reversing Epiretinal Membrane Formation - Described herein are treatment methods involving the administration of nicotinamide, which has been discovered to stabilize the normal phenotype of retinal pigment epithelial cells and to prevent retinal pigment epithelial cell proliferation. Diseases and disorders that can be treated according to the methods disclosed herein include, e.g., macular pucker, proliferative vitreoretinopathy, preretinal fibrosis, vitreomacular traction, tractional retinal detachment, and phthsis bulbi, cystoid macular edema (CME) arising from intraocular inflammation due to uveitis, vasculitis, trauma, surgery, and collagen vascular disease (e.g., Behcets disease or sarcoidosis), and age related macular degeneration. | 05-28-2015 |
Patent application number | Description | Published |
20120072851 | SYSTEM AND METHOD FOR CUSTOMIZING AN INTERFACE RELATED TO ACCESSING, MANIPULATING AND VIEWING INTERNET AND NON-INTERNET RELATED INFORMATION - A system and method are disclosed for accessing, generating, presenting and manipulating Internet and non-Internet related information, data and content, including information netcast over the Internet. The system is also capable of controlling operatively connected, privately networked devices. A number of graphical user interfaces are utilized to facilitate user access, manipulation and control of information, data and content and networked devices. Some of the graphical user interfaces are time and topic oriented, are customizable by the user, and allow for the manipulation of information, data, content and operatively connected networked devices from the graphical interfaces themselves. The system is preferably enhanced through the use of an intelligent, dynamically updated user profile that is fully integrated with the system. | 03-22-2012 |
20150205469 | System And Method For Customizing An Interface Related To Accessing, Manipulating, And Viewing Internet And Non-Internet Information - A method and medium are disclosed for accessing, generating, presenting and manipulating Internet and non-Internet related information, data and content, including information netcast over the Internet. A number of graphical user interfaces are utilized to facilitate user access, manipulation and control of information, data and content and networked devices. Some of the graphical user interfaces are time and topic oriented, are customizable by the user, and allow for the manipulation of information, data, content, and operatively connected networked devices from the graphical interfaces themselves. The system is preferably enhanced through the use of an intelligent, dynamically updated user profile that is fully integrated with the system. | 07-23-2015 |
Patent application number | Description | Published |
20100143552 | Edible Pet Chew - An edible pet chew | 06-10-2010 |
20110262587 | Edible Pet Chew Made From A Single Initially Malleable Sheet - An edible pet chew has a single sheet of a hardened chewable material dimensioned large enough and thin enough to be initially malleable for flexing, folding or rolling into a final shape. The single sheet is shaped into a final shape by flexing, folding or rolling and then hardened. | 10-27-2011 |
20120085296 | Edible Pet Chew - An edible pet chew | 04-12-2012 |
20130142936 | Edible Pet Chew Made From An Edible Malleable Sheet - An edible pet chew has an initially malleable sheet of a hardened chewable material dimensioned large enough and thin enough to be initially malleable for flexing, folding or rolling into a final shape. The sheet is shaped into a final shape by flexing, folding or rolling and then hardened. | 06-06-2013 |
20140137810 | Edible Pet Chew - A method of forming an edible pet chew that has a first casing of rawhide-free edible material and a second protein of flavored material for example jerky that is wrapped with the first sheet to form alternating layers in the edible pet chew. | 05-22-2014 |
Patent application number | Description | Published |
20120003736 | METHODS FOR CULTURING UNDIFFERENTIATED CELLS USING SUSTAINED RELEASE COMPOSITIONS - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state. | 01-05-2012 |
20120101024 | Methods and Compositions for Differentiating Embryonic Stem Cells - Methods and compositions for differentiating mammalian stem and progenitor cells are provided. More particularly, methods and compositions for obtaining neural cells from human embryonic stem cells are provided. | 04-26-2012 |
20130337562 | METHODS FOR CULTURING UNDIFFERENTIATED CELLS USING SUSTAINED RELEASE COMPOSITIONS - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state. | 12-19-2013 |
20150051212 | Compositions And Methods For Inhibiting Drusen - Described herein are methods for inhibiting drusen. | 02-19-2015 |
20150064784 | Methods For Culturing Undifferentiated Cells Using Sustained Release Compositions - Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state. | 03-05-2015 |
20150148383 | Methods for Inhibiting or Reversing Epiretinal Membrane Formation - Described herein are treatment methods involving the administration of nicotinamide, which has been discovered to stabilize the normal phenotype of retinal pigment epithelial cells and to prevent retinal pigment epithelial cell proliferation. Diseases and disorders that can be treated according to the methods disclosed herein include, e.g., macular pucker, proliferative vitreoretinopathy, preretinal fibrosis, vitreomacular traction, tractional retinal detachment, and phthsis bulbi, cystoid macular edema (CME) arising from intraocular inflammation due to uveitis, vasculitis, trauma, surgery, and collagen vascular disease (e.g., Behcets disease or sarcoidosis), and age related macular degeneration. | 05-28-2015 |